Innoviva's Q4 2019 results showed a decrease in RELVAR®/BREO® ELLIPTA® global net sales by 18% and a 2% decline in ANORO® ELLIPTA® global net sales. However, TRELEGY® ELLIPTA® global net sales were $221.4 million. Despite challenges, the company's full-year income from operations rose, cash resources increased, and debt levels declined.
RELVAR®/BREO® ELLIPTA® global net sales decreased 18% versus Q4 2018, with U.S. sales declining 42% and non-U.S. sales increasing 11%.
ANORO® ELLIPTA® global net sales declined 2% in Q4 2019, with U.S. sales declining 7% and non-U.S. sales growing 9%.
TRELEGY® ELLIPTA® global net sales were $221.4 million.
Innoviva's full-year income from operations rose, cash resources increased, and debt levels declined despite new generic entrants.
Analyze how earnings announcements historically affect stock price performance